ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL

1 November 2017 07:00 GMT

ASTRAZENECA AND ASPEN COMPLETE AGREEMENT FOR
RESIDUAL RIGHTS TO ANAESTHETIC MEDICINES

AstraZeneca today announced that it has completed the commercialisation agreement  (announced 14 September 2017) with Aspen Global Incorporated (AGI), part of the Aspen Group, under which AGI has acquired the residual rights to established anaesthetic medicines comprising of Diprivan , EMLA, Xylocaine / Xylocard / Xyloproct , Marcaine , Naropin , Carbocaine and Citanest.

AstraZeneca initially entered an  agreement  with AGI in June 2016, under which AGI gained the exclusive commercialisation rights to the medicines in markets outside the US. Under the terms of the new agreement, AGI has now acquired the remaining rights to the intellectual property and manufacturing know-how related to the anaesthetic medicines.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Esra Erkal-Paler UK/Global +44  203 749 5638
Karen Birmingham UK/Global +44  203 749 5634
Rob Skelding UK/Global +44   203 749 5821
Matt Kent UK/Global +44   203 749 5906
Gonzalo Viña UK/Global +44   203 749 5916
Jacob Lund Sweden +46   8 553 260 20
Michele Meixell US +1   302 885 2677
Investor Relations
Thomas   Kudsk Larsen +44 203 749 5712
Craig   Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry   Wheeler Oncology +44 203 749 5797
Mitchell   Chan Oncology +1   240 477 3771
Christer   Gruvris Diabetes; Autoimmunity, Neuroscience & Infection +44 203 749 5711
Nick   Stone Respiratory; Brilinta +44 203 749 5716
US   toll free +1   866 381 7277

Adrian Kemp

Company Secretary

AstraZeneca PLC

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links